161 related articles for article (PubMed ID: 28315947)
1. Impact of
Forschner A; Olthof SC; Gückel B; Martus P; Vach W; la Fougère C; Nikolaou K; Keim U; Eigentler TK; Garbe C; Pfannenberg C
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1312-1318. PubMed ID: 28315947
[TBL] [Abstract][Full Text] [Related]
2. Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma.
Schüle SC; Eigentler TK; Garbe C; la Fougère C; Nikolaou K; Pfannenberg C
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):482-8. PubMed ID: 26384681
[TBL] [Abstract][Full Text] [Related]
3. Influence of
Olthof SC; Forschner A; Martus P; Garbe C; Nikolaou K; la Fougère C; Gückel B; Vach W; Pfannenberg C
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2313-2321. PubMed ID: 32123968
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG-PET/CT in the Staging and Management of Melanoma: A Prospective Multicenter Ontario PET Registry Study.
Singnurkar A; Wang J; Joshua AM; Langer DL; Metser U
Clin Nucl Med; 2016 Mar; 41(3):189-93. PubMed ID: 26447374
[TBL] [Abstract][Full Text] [Related]
5. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy.
Finkelstein SE; Carrasquillo JA; Hoffman JM; Galen B; Choyke P; White DE; Rosenberg SA; Sherry RM
Ann Surg Oncol; 2004 Aug; 11(8):731-8. PubMed ID: 15249335
[TBL] [Abstract][Full Text] [Related]
6. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.
Deckers EA; Wevers KP; Muller Kobold AC; Damude S; Vrielink OM; van Ginkel RJ; Been LB; van Leeuwen BL; Hoekstra HJ; Kruijff S
J Surg Oncol; 2019 Nov; 120(6):1031-1037. PubMed ID: 31468535
[TBL] [Abstract][Full Text] [Related]
7. The utility of PET-CT in the staging and management of advanced and recurrent malignant melanoma.
Twycross SH; Burger H; Holness J
S Afr J Surg; 2019 Sep; 57(3):44-49. PubMed ID: 31392864
[TBL] [Abstract][Full Text] [Related]
8. CT texture analysis compared to Positron Emission Tomography (PET) and mutational status in resected melanoma metastases.
Olthof SC; Krumm P; Weichold O; Eigentler T; Bösmüller H; la Fougère C; Pfannenberg C; Martus P; Klumpp B
Eur J Radiol; 2020 Oct; 131():109242. PubMed ID: 32942199
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Prognostic Value of
Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
[TBL] [Abstract][Full Text] [Related]
10.
Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
[TBL] [Abstract][Full Text] [Related]
11. The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanoma.
Stahlie EHA; van der Hiel B; Stokkel MPM; Schrage YM; van Houdt WJ; Wouters MW; van Akkooi ACJ
J Surg Oncol; 2020 Dec; 122(7):1328-1336. PubMed ID: 32783266
[TBL] [Abstract][Full Text] [Related]
12. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging.
Bronstein Y; Ng CS; Rohren E; Ross MI; Lee JE; Cormier J; Johnson VE; Hwu WJ
AJR Am J Roentgenol; 2012 Apr; 198(4):902-8. PubMed ID: 22451559
[TBL] [Abstract][Full Text] [Related]
13. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
14. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.
Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635
[TBL] [Abstract][Full Text] [Related]
16. Interim [
Sachpekidis C; Kopp-Schneider A; Pan L; Papamichail D; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1932-1943. PubMed ID: 33336264
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
18. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
Kalff V; Hicks RJ; MacManus MP; Binns DS; McKenzie AF; Ware RE; Hogg A; Ball DL
J Clin Oncol; 2001 Jan; 19(1):111-8. PubMed ID: 11134203
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point
Cho SY; Lipson EJ; Im HJ; Rowe SP; Gonzalez EM; Blackford A; Chirindel A; Pardoll DM; Topalian SL; Wahl RL
J Nucl Med; 2017 Sep; 58(9):1421-1428. PubMed ID: 28360208
[TBL] [Abstract][Full Text] [Related]
20. Whole-Body [
Berzaczy D; Fueger B; Hoeller C; Haug AR; Staudenherz A; Berzaczy G; Weber M; Mayerhoefer ME
Mol Imaging Biol; 2020 Jun; 22(3):739-744. PubMed ID: 31363965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
